<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-180-8-39-44</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-1423</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Выраженность биомаркеров неалкогольного стеатоза печени у больных с ожирением, стабильной стенокардией напряжения и стенозирующим атеросклерозом сонных артерий</article-title><trans-title-group xml:lang="en"><trans-title>The severity of biomarkers of non-alcoholic hepatic steatosis in patients with obesity, stable exertional angina and stenosing atherosclerosis of the carotid arteries</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зыкина</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Zykina</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зыкина Елена Юрьевна - аспирант кафедры госпитальной терапии.</p><p>610998, Киров, ул. К. Маркса, д. 112</p></bio><bio xml:lang="en"><p>Elena Yu. Zykina - post-graduate of the Department of Hospital Therapy.</p><p>610998, Kirov, K. Marx Street, 112</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9772-3867</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симонова</surname><given-names>Ж. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Simonova</surname><given-names>Zh. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симонова Жанна Георгиевна - доктор медицинских наук, доцент, профессор кафедры госпитальной терапии</p><p>610998, Киров, ул. К. Маркса, д. 112</p></bio><bio xml:lang="en"><p>Zhanna G. Simonova - doctor of medical sciences, professor of the Department of Hospital Therapy.</p><p>610998, Kirov, K. Marx Street, 112</p></bio><email xlink:type="simple">simonova-kirov@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Кировский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kirov state medical university of the Ministry of Health of the Russian Federation (FSBEI HE Kirov SMU MOH Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2020</year></pub-date><volume>0</volume><issue>8</issue><fpage>39</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зыкина Е.Ю., Симонова Ж.Г., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Зыкина Е.Ю., Симонова Ж.Г.</copyright-holder><copyright-holder xml:lang="en">Zykina E.Y., Simonova Z.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/1423">https://www.nogr.org/jour/article/view/1423</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: изучить прогностическую ценность биомаркеров неалкогольного стеатоза печени в оценке выраженности атеросклероза общей сонной артерии у больных стабильной стенокардией и ожирением.</p><p>Материалы и методы исследования. В процессе исследования сформированы две группы больных. I группу составили больные стабильной стенокардией с сопутствующим ожирением (n=24). II группу (n=35) составили больные стабильной стенокардией, имевшие нормальный индекс массы тела (ИМТ). Оценивали: показатели функции печени, углеводного и липидного обменов, результаты дуплексного сканирования экстракраниального отдела брахиоцефальных артерий (БЦА), рассчитывали биомаркеры стеатоза: печеночный индекс стеатоза (HSI), индексы TyG, BARD, BAAT, VAI. Всем больным выполняли ультразвуковое исследование печени (УЗИ).</p></sec><sec><title>Результаты</title><p>Результаты. У 100% больных I группы на основании УЗИ был выявлен стеатоз печени. Биомаркеры стеатоза печени (HSI, TyG, BARD, BAAT, VAI) оказались более выражены у больных I группы и подтвердили наличие стеатоза печени. Также среди больных I группы установлены: более выраженные нарушения функционального состояния печени, более значимая гипертриглицеридемия. У больных I группы выявлены более существенные атеросклеротические изменения ОСА. Атеросклеротические бляшки по данным УЗДС БЦА с большей частотой были установлены у пациентов I группы в сравнении со II группой (70,8% vs 40%). Доля больных со значимым стенозом (&gt;50% просвета сосуда) в I группе оказалась значимо больше и составила 33,3%.</p></sec><sec><title>Заключение</title><p>Заключение. У больных стабильной стенокардией в сочетании с ожирением, при нарушении функциональных параметров печени, выраженной гипертриглицеридемии, неинвазивные биомаркеры скрининга неалкогольного стеатоза печени позволяют подтвердить наличие ранних морфологических изменений печени, а также прогнозировать более выраженные атеросклеротические изменения общей сонной артерии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The aim of the study</title><p>The aim of the study: to study the prognostic value of biomarkers of non-alcoholic liver steatosis in assessing the expression of atherosclerosis of the general carotid artery in patients with stable angina and obesity.</p><p>Materials and methods of research. Two groups of patients were formed during the study. Group I was made up of patients with stable angina with concomitant obesity (n = 24). Group II (n = 35) were stable angina patients with normal body mass index (BMI). Liver function, carbohydrate and lipid exchanges, duplex scanning results of the extracranial brachyocephalic artery (BCA) were evaluated, and biomarkers of steatosis were calculated: hepatic steatosis index (HSI), TyG indices, BARD, BAAT, VAI. Ultrasound of the liver (ultrasound) was performed on all patients.</p></sec><sec><title>Results</title><p>Results. 100% of group I patients showed liver steatosis based on ultrasound. Biomarkers of liver steatosis (HSI, TyG, BARD, BAAT, VAI) were more severe in group I patients and conﬁ rmed the presence of liver steatosis. Also among the patients of group I found: more pronounced disorders of functional state of liver, more signiﬁ cant hypertriglyceridemia. More signiﬁ cant atherosclerotic changes in OCA were detected in group I patients. Atherosclerotic plaques were more frequently found in group I patients compared to group II patients (70.8% vs 40%). The proportion of patients with signiﬁ cant stenosis (&gt; 50% of the vessel lumen) in group I was signiﬁ cantly higher and amounted to 33.3%.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with stable angina combined with obesity, in case of liver functional parameters disorder, pronounced hypertriglyceridemia, non-invasive biomarkers of liver non-alcoholic steatosis screening allow conﬁ rming the presence of early morphological liver changes, as well as predicting more pronounced atherosclerotic changes of the common carotid artery.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>атеросклероз</kwd><kwd>общая сонная артерия</kwd><kwd>ожирение</kwd><kwd>стабильная стенокардия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>atherosclerosis</kwd><kwd>common carotid artery</kwd><kwd>obesity</kwd><kwd>stable angina</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sanyal A. J. NASH: A global health problem. Hepatology Research. 2011;41(7):670-674. DOI: 10.1111/i.1872-034X.2011.00824.X.</mixed-citation><mixed-citation xml:lang="en">Sanyal A. J. NASH: A global health problem. Hepatology Research. 2011;41(7):670-674. DOI: 10.1111/i.1872-034X.2011.00824.X.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Farrell G. C, barter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. J. Hepatol. 2006; 43: 99-112. DOI: 10.1002/hep.20973.</mixed-citation><mixed-citation xml:lang="en">Farrell G. C, barter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. J. Hepatol. 2006; 43: 99-112. DOI: 10.1002/hep.20973.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т., Драпкина О. М., Маев И. В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 //Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии. -2015. - № 6. - С. 31-41.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Drapkina O. M., Maiev I. V., et al. The prevalence of nonalcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: results of the DIREG 2 trial. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 6: 31-41. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lonardo A., Ballestri S., Marchesini G., Angulo P. and Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease. 2015; 47: 181-190. DOI:10.1016/j.dld.2014.09.020.</mixed-citation><mixed-citation xml:lang="en">Lonardo A., Ballestri S., Marchesini G., Angulo P. and Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease. 2015; 47: 181-190. DOI:10.1016/j.dld.2014.09.020.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Targer G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The new England Journal of Medicine. 2010; 363:1341-1350. DOI: 10.1056/NEJMra0912063.</mixed-citation><mixed-citation xml:lang="en">Targer G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The new England Journal of Medicine. 2010; 363:1341-1350. DOI: 10.1056/NEJMra0912063.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113-121. DOI: 10.1053/j.gastro.</mixed-citation><mixed-citation xml:lang="en">Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113-121. DOI: 10.1053/j.gastro.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi Z. M. Longterm follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology. 2009; 7:234-238. DOI: 10.1016/j.cgh.2008.11.005.</mixed-citation><mixed-citation xml:lang="en">Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi Z. M. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology. 2009; 7:234-238. DOI: 10.1016/j.cgh.2008.11.005.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Кардиоваскулярная профилактика 2017. Российские национальные рекомендации// Российский кардиологический журнал. -2018. -Т.23. - № 6. - С. 7-122. Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018; (6):7-122. (In Russ.). DOI:10.15829/1560-4071-2018-6-7-122.</mixed-citation><mixed-citation xml:lang="en">Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018; (6):7-122. (In Russ.). DOI:10.15829/1560-4071-2018-6-7-122.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.</mixed-citation><mixed-citation xml:lang="en">EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cadranel J. F. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterologie Clinique Biologique. 2002; 26:823-824. DOI: GCB-10-2002-26-10-0399-8320-101019-ART1.</mixed-citation><mixed-citation xml:lang="en">Cadranel J. F. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterologie Clinique Biologique. 2002; 26:823-824. DOI: GCB-10-2002-26-10-0399-8320-101019-ART1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo A.A, Sheth S.G, Chopra S. Liver biopsy. The new England Journal of Medicine. 2001;344 (7):495-500. DOI: 10.1056/NEJM200102153440706.</mixed-citation><mixed-citation xml:lang="en">Bravo A.A, Sheth S.G, Chopra S. Liver biopsy. The new England Journal of Medicine. 2001;344 (7):495-500. DOI: 10.1056/NEJM200102153440706.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fedchuk L., Nascimbeni F., Pais R., Charlotte F. et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. Pharm. Ther. 2014; 40: 1209-1222. DOI:10.1111/apt.12963</mixed-citation><mixed-citation xml:lang="en">Fedchuk L., Nascimbeni F., Pais R., Charlotte F. et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. Pharm. Ther. 2014; 40: 1209-1222. DOI:10.1111/apt.12963</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B., Mancia G., Spiering W. et al. 2018 ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. European Heart Journal. 2018; 39 (33): 3021-3104. DOI: 10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B., Mancia G., Spiering W. et al. 2018 ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. European Heart Journal. 2018; 39 (33): 3021-3104. DOI: 10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Amato M. C., Giordano C., Galia M., Criscimanna A., Vitabile S. et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33: 920-922.</mixed-citation><mixed-citation xml:lang="en">Amato M. C., Giordano C., Galia M., Criscimanna A., Vitabile S. et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiomet-abolic risk. Diabetes Care. 2010; 33: 920-922.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Adams L.A., George J., Bugianesi E., et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011; 26: 536-1543. DOI: 10.1111/j.1440-1746.2011.06774.x.</mixed-citation><mixed-citation xml:lang="en">Adams L.A., George J., Bugianesi E., et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011; 26: 536-1543. DOI: 10.1111/j.1440-1746.2011.06774.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison S. A., Oliver D., Arnold H. L., Gogia S., Neuschwander-Tetri B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57: 1441-1447. DOI: 10.1136/gut.2007.146019.</mixed-citation><mixed-citation xml:lang="en">Harrison S. A., Oliver D., Arnold H. L., Gogia S., Neuschwander-Tetri B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57: 1441-1447. DOI: 10.1136/gut.2007.146019.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Корнеева О. Н. Континиум неалкогольной жировой болезни печени: от стеатоза до сердечно-сосудистого риска// Рациональная фармакотерапия в кардиологии. - 2016. -Т. 12. -№ 4. -С. 424-429.</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Korneeva O. N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration Pharmacother Cardiol. 2016;12(4):424-429. (In Russ.). DOI: 10.20996/1819-6446-2016-12-4-424-429.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Drapkina O. M., Korneeva O. N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration Pharmacother Cardiol. 2016;12(4):424-429. (In Russ.). DOI: 10.20996/1819-6446-2016-12-4-424-429.</mixed-citation><mixed-citation xml:lang="en">Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014; 59:121-129. DOI: 10.1002/hep.26510.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014; 59:121-129. DOI: 10.1002/hep.26510.</mixed-citation><mixed-citation xml:lang="en">Kumar R. et al. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. Journal of Clinical and Translational Hepatology. 2020;8: 76-86. DOI: 10.14218/JCTH.2019.00051.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar R. et al. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. Journal of Clinical and Translational Hepatology. 2020;8: 76-86. DOI: 10.14218/JCTH.2019.00051.</mixed-citation><mixed-citation xml:lang="en">Oni E.T, Agatston A.S, Blaha M.J, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230:258-267. DOI: 10.1016/уатеросклероз.2013.07.052.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Oni E.T, Agatston A.S, Blaha M.J, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230:258-267. DOI: 10.1016/уатеросклероз.2013.07.052.</mixed-citation><mixed-citation xml:lang="en">Oni E.T, Agatston A.S, Blaha M.J, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230:258-267. DOI: 10.1016/уатеросклероз.2013.07.052.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
